Kura Oncology, Inc. $KURA Holdings Lifted by Hsbc Holdings PLC

Hsbc Holdings PLC increased its stake in Kura Oncology, Inc. (NASDAQ:KURA) by 26.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 54,491 shares of the company’s stock after acquiring an additional 11,406 shares during the period. Hsbc Holdings PLC owned approximately 0.06% of Kura Oncology worth $351,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. E Fund Management Co. Ltd. boosted its holdings in shares of Kura Oncology by 18.9% in the first quarter. E Fund Management Co. Ltd. now owns 12,252 shares of the company’s stock valued at $81,000 after acquiring an additional 1,951 shares in the last quarter. MetLife Investment Management LLC boosted its holdings in shares of Kura Oncology by 6.6% in the fourth quarter. MetLife Investment Management LLC now owns 44,828 shares of the company’s stock valued at $390,000 after acquiring an additional 2,776 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Kura Oncology by 8.3% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 47,031 shares of the company’s stock valued at $408,000 after acquiring an additional 3,617 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of Kura Oncology by 18.3% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 28,070 shares of the company’s stock valued at $245,000 after acquiring an additional 4,344 shares in the last quarter. Finally, Rhumbline Advisers boosted its holdings in shares of Kura Oncology by 5.2% in the first quarter. Rhumbline Advisers now owns 105,206 shares of the company’s stock valued at $694,000 after acquiring an additional 5,215 shares in the last quarter.

Kura Oncology Stock Up 6.0%

Shares of NASDAQ:KURA opened at $8.43 on Thursday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.16 and a current ratio of 6.16. The company has a market cap of $731.72 million, a PE ratio of -3.73 and a beta of 0.19. Kura Oncology, Inc. has a 52 week low of $5.41 and a 52 week high of $21.40. The firm has a 50 day simple moving average of $6.57 and a 200 day simple moving average of $6.58.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of $0.15 by ($0.90). The company had revenue of $15.29 million for the quarter, compared to analyst estimates of $64.95 million. As a group, research analysts expect that Kura Oncology, Inc. will post -2.44 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. Mizuho decreased their price objective on shares of Kura Oncology from $32.00 to $30.00 and set an “outperform” rating for the company in a report on Monday, May 19th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a report on Thursday, June 26th. Wall Street Zen upgraded shares of Kura Oncology from a “sell” rating to a “hold” rating in a report on Sunday, August 17th. Wedbush restated an “outperform” rating and set a $36.00 target price on shares of Kura Oncology in a report on Friday, June 20th. Finally, JMP Securities reduced their target price on shares of Kura Oncology from $28.00 to $24.00 and set a “market outperform” rating for the company in a report on Monday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $24.10.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.